# Animal Testing

Type: Technology

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/animal-testing
Canonical HTML page: https://getbiobrief.com/entity/animal-testing

## Timeline

- **2027 (projected)**: Hybrid Submission Standards — Expected formalization of regulatory pathways that prioritize NAM data over animal data for specific drug classes.
- **2025**: OOC Commercialization — Widespread adoption of organ-on-a-chip systems in early-stage pharmaceutical R&D for toxicity screening.
- **2023**: EU Regulatory Shift — The European Parliament and EMA accelerate roadmaps for the phase-out of animal use in regulatory testing.
- **2022-12**: FDA Modernization Act 2.0 — President Biden signs legislation removing the requirement for animal testing for biosimilars and new drugs.

## Recent coverage (1 stories)

### Regulatory Momentum for Animal-Free Testing Outpaces Current Technology
2026-03-20 16:26:48 · Sentiment: Neutral · Impact: 6/10 · Sources: 2

The pharmaceutical industry is navigating a historic shift as the FDA Modernization Act 2.0 removes the mandate for animal testing in drug development. However, while technologies like organ-on-a-chip and AI offer higher human predictivity, they currently lack the systemic complexity required to fully replace animal models in late-stage safety assessments.
Full story: https://getbiobrief.com/story/animal-testing-alternatives-regulatory-gap

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.